Clinical trials: Gastric Cancer, completed
Stomach Neoplasms
Botulinum Toxin for Stomach Cancer Treatment
Preclinical studies at our institution, using a genetic mouse model of gastric cancer, strongly suggest that innervation of the stomach wall is required not only for the development, but also for the progression of gastric…
- Trial name
- NCT01822210
- Testing
- Botox
- Where
- Norway
- Volunteers
- 7 people
- Sponsor
- St. Olavs Hospital
Gastric Neoplasms, Pancreatic Neoplasms
A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma
This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety and tolerability of ASG-5ME and identify the maximum tolerated dose in patients with pathologically confirmed metastatic pancreatic…
- Trial name
- NCT01166490
- Testing
- ASG-5ME
- Where
- 7 sites in United States
- Volunteers
- 51 people
- Sponsor
- Seagen Inc.
Gastric Cancer
The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer
This study is designed to compare the efficacy and safety of XELOX regimen with EOX regimen in the first-line treatment of advanced gastric cancer patients.
- Trial name
- NCT02395640
- Testing
- Epirubicin, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 438 people
- Sponsor
- Fudan University
Gastric Cancer
A Trial of Induction Chemotherapy and Chemoradiotherapy With TS-1 and Cisplatin (SP) as First-line Treatment in Patients With High Risk Advanced Gastric Cancer
A Phase I trial of Induction chemotherapy and Chemoradiotherapy with TS-1 and Cisplatin (SP) as first-line treatment in patients with high risk advanced gastric cancer.
- Trial name
- NCT01269255
- Testing
- TS-1 with Cisplatin
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- Yonsei University
Chemotherapy Effect
Feasibility and Safety of Neoadjuvant Chemotherapy (FLOT ) for Gastric Cancer Patients in China
Neoadjuvant chemotherapy for advanced-stage gastric cancer is justified by various studies, however, there was not any large scale randomized controlled trial (RCT) to support it until German oncologist introduced a novel…
- Trial name
- NCT03646591
- Testing
- Chemotherapy
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Ruijin Hospital
Advanced Gastric Cancer
Biweekly FOLFIRI in Advanced Gastric Cancer (AGC) With Failure of Prior Taxane, Fluoropyrimidine, and Cisplatin
The purpose of this study is: To observe the feasibility of biweekly oxaliplatin and infusional 5-fluorouracil (FU)/Leucovorin (LV) in patients with advanced gastric adenocarcinoma who have prior exposure to taxane…
- Trial name
- NCT00976768
- Testing
- oxaliplatin, 5-fluorouracil
- Where
- South Korea
- Volunteers
- 44 people
- Sponsor
- Asan Medical Center
Gastric Cancer
Gastric Cancer Surgery in Elderly Patients
Gastric cancer is most frequent after the fifth decade of life. Surgical risk is higher in aged population because of general health condition may affect the postoperative result.
- Trial name
- GCSEP (NCT03777540)
- Testing
- Gastric resection
- Volunteers
- 236 people
- Sponsor
- University of Bologna
Gastric Cancer
Validation of a Model for Predicting Anastomotic Leakage
This study will validate a machine learning model for predicting anastomotic leakage of esophagogastrostomy and esophagojejunostomy.
- Trial name
- NCT05646290
- Where
- China
- Volunteers
- 512 people
- Sponsor
- Jichao Qin
Helicobacter Infection
Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection
Helicobacter pylori is a bacteria that infects the lining of the stomach and is associated with ulcers. Helicobacter pylori may also increase the long-term risk of developing certain forms of gastric cancer.
- Trial name
- 960025 (NCT00656968)
- Testing
- 10-day sequential treatment, 10-day concomitant therapy
- Where
- 2 sites in Taiwan
- Volunteers
- 232 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Achlorhydria, Gastrinoma
Evaluating Patients With Abnormal Levels of Gastric Acid
This study is used by the Digestive Diseases Branch to evaluate patients with suspected abnormalities in the secretion of gastric acid.
- Conditions
- Achlorhydria, Gastrinoma, Zollinger Ellison Syndrome
- Trial name
- NCT00001240
- Where
- United States
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Stomach Neoplasms, Cancer Survivors
Development and Testing of a Social Cognitive Theory-based Dietary Behavioral Intervention in Gastric Cancer Survivors
This study aims to develop a Social Cognitive Theory (SCT)-based dietary behavioral intervention for gastric cancer survivors, and explore the feasibility, acceptability, and preliminary effectiveness of delivering this…
- Trial name
- NCT04985084
- Testing
- The intervention group, Usual care
- Where
- China
- Volunteers
- 35 people
- Sponsor
- The Hong Kong Polytechnic University
Breast Cancer, Colorectal Cancer, Gastric Cancer
An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer, Colon Cancer in the Adjuvant Setting, Advanced Gastric Cancer or Breast Cancer
This multi-center observational study will evaluate the use of Xeloda (capecitabine) in patients with metastatic colorectal cancer, colon cancer in the adjuvant setting, advanced gastric cancer and breast cancer in routine…
- Trial name
- NCT01664494
- Testing
- Capecitabine
- Where
- Austria
- Volunteers
- 563 people
- Sponsor
- Hoffmann-La Roche
Gastric Cancer
High-Dose Chemotherapy in Treating Patients With Advanced Stomach Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving higher doses may kill more tumor cells.
- Trial name
- NCT00002722
- Testing
- cisplatin, fluorouracil, leucovorin calcium
- Volunteers
- 135 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Gastric Cancer
Weekly Docetaxel/Irinotecan for Non-resectable Gastric Cancers After Cisplatin Plus 5-FU/Leucovorin
In this study, the investigators will use P-HDFL, a regimen with high tumor remission rate (~ 60-70%) and with only modest treatment-associated toxicities, as induction chemotherapy for patients with non-resectable gastric…
- Trial name
- P-HDFL-DI (NCT00166881)
- Testing
- Docetaxel-Irinotecan
- Where
- Taiwan
- Volunteers
- 29 people
- Sponsor
- National Taiwan University Hospital
Pleural Effusion, Malignant, Ascites, Malignant
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations…
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular
- Trial name
- TraveraRTGx (NCT05461430)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Travera Inc
Gastric Cancer
Neo-Sequence 1: Neoadjuvant Chemotherapy With or Without Antiangiogenesis and Sequential Immunotherapy for HER2-negative MMR-proficient Locally Advanced Gastric or Gastroesophageal Adenocarcinoma
This is a single-institution, prospective phase II trial designed to evaluate the efficacy of neoadjuvant chemotherapy and sequential immunotherapy in patients with locally advanced esophagogastric junction and gastric…
- Trial name
- NCT05540145
- Testing
- SOX plus Paclitaxel with or without antiangiogenesis followed by PD-1 antibody
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Neoplasms, Adenocarcinoma of the Gastroesophageal Junction
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab
A study to evaluate the safety and tolerability of DKN-01 in combination with weekly paclitaxel or pembrolizumab in participants with relapsed or refractory Esophagogastric Malignancies
- Conditions
- Esophageal Neoplasms, Adenocarcinoma of the Gastroesophageal Junction, Gastroesophageal Cancer, Squamous Cell Carcinoma
- Trial name
- P102 (NCT02013154)
- Testing
- DKN-01 150 mg, Paclitaxel, Pembrolizumab
- Where
- 10 sites in United States
- Volunteers
- 151 people
- Sponsor
- Leap Therapeutics, Inc.
Healthy
A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.
The purpose of this study is to assess the potential effect and safety of multiple oral doses of dexlansoprazole, lansoprazole, omeprazole or esomeprazole, once daily (QD), on the steady-state pharmacokinetics and…
- Trial name
- NCT00942175
- Testing
- Clopidogrel, Clopidogrel and Lansoprazole, Clopidogrel and Dexlansoprazole
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Takeda
Oesophageal Cancer, Oesophageal Disease
EndoVE endosCopic Treatment for Oesophageal and Gastric canceR
This project aims to establish the safety and efficacy of treating patients with inoperable oesophageal cancer or gastric cancer, using an endoscopic electroporation system (EndoVE) to facilitate direct chemotherapy tumour…
- Conditions
- Oesophageal Cancer, Oesophageal Disease, Gastric Cancer
- Trial name
- VECTOR (NCT04649372)
- Testing
- EndoVE
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Mirai Medical
GastroEsophageal Cancer, Gastric Cancer
A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies
This is an open label, single arm phase II study, to determine the overall response rate for the combination of lenvatinib and pemrolizumab in patients with metastatic gastroesophageal cancer who have progressed on first or…
- Trial name
- NCT03321630
- Testing
- Lenvatinib, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- NYU Langone Health
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.